

From: [Kleingbiel-Senekal, Lizel \[lizelk@sun.ac.za\]](mailto:lizelk@sun.ac.za)
Subject: Calls: NIH health related funding opportunities: NIH#12-16
Date: Monday, 07 June 2021 13:30:17
Attachments: [image006.png](#)
[16 NIH 2021 06 07.pdf](#)
[15 NIH 2021 05 31.pdf](#)
[14 NIH 2021 05 24.pdf](#)
[13 NIH 2021 05 17.pdf](#)
[12 NIH 2021 05 12.pdf](#)

Dear colleagues

Herewith attached please find information on the current open **National Institutes of Health (NIH)** calls.

- The NIH funding opportunities attached are only a selection of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For NIH and other funding opportunities, please link to the Medical Faculty's web page: www.sun.ac.za/RDSfunding.
- Please note that the application process is comprehensive. For more information on how to navigate the grant application process, visit www.grants.nih.gov
- **Confirm your intent to apply not later than 60 days before the submission date.**
- This information has already been sent to researchers at the **Tygerberg Campus** and the contact person is **Christa de Vries**: cdevries@sun.ac.za
- Researchers at the Main Campus can contact me for more information: lizelk@sun.ac.za.

Kind regards

Lizél (Kleingbiel) Senekal | MPhil Science & Technology Studies (Science Communication)
Coordinator: EU & other international research funding
Division for Research Development
t: +27 21 808 2105 | a: 2041 Wilcocks Building, Ryneveld Street, Stellenbosch, South Africa



The integrity and confidentiality of this email are governed by these terms. [Disclaimer](#)
Die integriteit en vertroulikheid van hierdie e-pos word deur die volgende bepalings bereël.
[Vrywaringsklousule](#)



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

12 May 2021 (#12)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Important Notices

- [NOT-OD-21-107](#) **Publication of the Revised NIH Grants Policy Statement (Rev. April 2021) for Fiscal Year 2021.** The NIHGPS provides both up-to-date policy guidance that serves as NIH standard terms and conditions of award for all NIH grants and cooperative agreements, and extensive guidance to those who are interested in pursuing NIH grants.
- **New funding from [Cures Within Reach](#): ReGRoW:** Repurposing Grants for the Rest of the World - Funding for Underserved Researchers in LMICs will support grants of up to \$50,000 each for clinical repurposing trials led by an underserved researcher in any LMIC. Proposal deadline: August 6, 2021. [More information](#)
- [NIH FY 2020 By the Numbers: Extramural Investments in Research](#)
- [NOT-OD-21-110](#) **Implementation of Changes to the Biographical Sketch and Other Support Format Page**
 - [Updated Biographical Sketch and Other Support Format Pages Available Now and Required January 2022](#)
- [All Senior/Key Personnel Required to Have A Commons ID Listed on Applications for Due Dates on Or After January 25, 2022](#)
- [NOT-DA-21-049](#) **Notice of Information: Establishment of a Standard THC Unit to be used in Research** Cannabis is a plant containing more than 500 chemicals, and more than 100 cannabinoids. Delta-9-Tetrahydrocannabinol (THC) is the main cannabinoid responsible for the psychotropic and addictive properties of cannabis. Inconsistency in the measurement and reporting of THC exposure has been a major limitation in studies of cannabis use.
- [NOT-OD-21-120](#) **Notice of Technical Assistance Webinar for NOT-OD-21-087, Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being NOSI.** A technical assistance webinar will be held on Tuesday, June 8, 2021, from 10:00 – 11:30 a.m. (Eastern Time) for all prospective applicants. Registration required.
- **The NIH Office of Intramural Training and Education (OITE) hosts a monthly seminar series, the [Mental Health and Well-being of Biomedical Researchers](#).** Sessions are free and open to NIH trainees, PIs and staff (intramural and extramural), as well as trainees, PIs and staff from universities and research institutions. Registration is required. Videos of past sessions are available on the [NIH OITE YouTube channel](#).

Notices of Special Interest (NOSI)

[NOT-AA-21-028](#) Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes. This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances. The purpose of the Notice is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This Notice is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through September 8, 2024. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

[NOT-CA-21-057](#) Biology of Lung and Head and Neck Preneoplasia This NOSI seeks applications investigating mechanistic and biological aspects of preneoplasia leading to invasive lung and head and neck (HN) cancers. Despite having better molecular understanding of lung and HN cancers and improved therapies for affected patients, these tumors remain a major health problem in the United States (US) and globally. Applications that are responsive to the NOSI include those focused on any areas related to:

- The mechanisms and biology of early and preinvasive stages of lung or HN carcinogenesis;
- Immune regulation of premalignancy at these anatomic sites; and/or
- Identification of potential targets or strategies for early intervention to intercept lung or HN oncogenesis.

Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

[NOT-CA-21-074](#) Early-life Factors and Cancer Development Later in Life. The purpose of this NOSI is to stimulate research focused on the roles of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Applications that will be considered nonresponsive to this NOSI will include:

- Studies that establish new cohorts.
- Studies that fund infrastructure for follow-up visits of an existing cohort.

Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PAR-21-190](#) - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- [PAR-19-277](#) - Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)
- [PA-20-195](#) - NIH Exploratory/Development Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PAR-20-052](#) - NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)

[NOT-HD-21-025](#) Reproductive Health, Pregnancy, and Parenting among Women with Disabilities. The purpose of this Notice of Special Interest (NOSI) is to encourage and support research studies in women with disabilities (WWD) in any of three interconnected areas of high priority to NICHD:

- Gynecologic care and preconception health for women and adolescent girls with disabilities
- Pregnancy in WWD
- Postpartum and parenting needs of WWD

It is not expected or required that all areas will be addressed in one application. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through May 31, 2024. Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-185](#) – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-183](#) – NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) – NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

- [PA-21-221](#) – NICHD Small Research Grant Program (R03 Clinical Trial Required)
- [PA-21-231](#) – NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)

NOT-HD-21-026 Research on the Impact of the Covid 19 Pandemic and Risks for Abuse and Injury Among Vulnerable Children and Youth. Treating injured and traumatized children and efforts to implement preventive interventions have become increasingly challenging in the context of the current pandemic. Children are notably at greater risk of injury, morbidity and mortality due to the social isolation, economic stressors, and other challenges related to policies and practices designed to mitigate the spread of the coronavirus. Given the limitations of traditional contexts for identifying and reporting abuse due to these mitigation strategies, research on treatment and care in diverse (e.g. primary, emergency and acute care) settings is essential to identify effective ways of screening, diagnosing and assessing trends in abuse and abuse related injuries in this current context. This notice applies to due dates on or after June 5, 2019 and subsequent receipt dates through May 31, 2024. Submit applications for this initiative using one of the following funding opportunity announcements

- [PA-20-185](#) – NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-183](#) – NIH Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) – NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-21-221](#) – NICHD Small Research Grant Program (R03 Clinical Trial Required)
- [PA-21-231](#) – NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
- [PA-20-195](#) – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-21-194](#) – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-21-196](#) – NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

NOT-DA-21-012 Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA) special interest in grant applications to conduct rigorous basic, translational and/or clinical research to: (1) advance identification of sex and/or gender differences in risk for substance use disorders or the response or medical consequences of alcohol or substance misuse to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This notice applies to due dates on or after June 5, 2021 and subsequent receipt dates through September 8, 2024. Submit applications for this initiative using one of the following funding opportunity announcements:

- [PA-20-184](#) - Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
- [PA-20-146](#) - NIDA Small Research Grant Program (R03 Clinical Trial Required)

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-223](#)

Type: U01

Application Due Date: June 05, 2021, October 05, 2021, February 05, 2022, June 05, 2022 October 05, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum request cannot exceed 5 years but the actual funded project period is dependent on reaching specific milestones as described in this FOA.

2. Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-229](#)

Type: R01

Application Due Date: June 05, 2021, February 05, 2022, June 05, 2022, February 05, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Rapid advances in genotyping and next generation sequencing technologies have led to the identification of genetic variants that are associated with a wide variety of congenital defects including structural birth defects (SBDs), intellectual developmental disabilities (IDDs) and inborn errors of metabolism (IEMs). Large quantities of genomic data collected from pediatric birth defects cohorts are available to the research community through several databases such as the Database of Genotypes and Phenotypes (dbGaP), the Gabriella Miller Kids First Data Resource Portal, the European Genome-Phenome Archive and Clinical Genome Resource (ClinGen). The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest.

Budget: Application budgets are limited to \$499,999 direct costs per year and need to reflect the actual needs of the proposed projects. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. National Institute of Neurological Disorders and Stroke (NINDS) Exploratory Clinical Trials (U01 - Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-236](#)

Type: U01

Application Due Date: June 05, 2021, October 05, 2021, February 05, 2022. **AIDS dates:** September 07, 2021, January 07, 2022, May 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<https://www.ninds.nih.gov/>). Examples of appropriate studies include, but are not limited to, those designed to:

- Evaluate and optimize the dose, formulation, safety, tolerability or pharmacokinetics of an intervention in healthy volunteers or the target population.
- Evaluate whether an intervention produces sufficient evidence of short-term activity (e.g., biomarker activity, target engagement, dose-response trends, pharmacodynamic response) in a human "proof of concept" trial.
- Select or rank the best of two or more potential interventions or dosing regimens to be evaluated in a subsequent trial, based on tolerability, biological activity, or preliminary clinical efficacy (e.g., futility trials).
- For devices: Establish proof-of-principle and optimize techniques, operation, and usability of a device; inform the final device design decisions; and estimate the magnitude of treatment effect.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum request cannot exceed 5 years.

4. Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trials Not Allowed

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-21-032](#)

Type: R01

Application Due Date: July 6, 2021 by 11:59 PM Eastern Time.

Funding Opportunity Announcement: Center for Biologics Evaluation and Research (CBER), FDA seeks to support the development of innovative pathogen reduction technologies for whole blood and blood components to prevent transfusion-transmitted infectious diseases.

Budget: Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): YR 01: \$4,000,000 and YR 02: \$4,000,000

5. Human Milk as a Biological System (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-22-020](#)

Type: R01

Application Due Date: November 29, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in our understanding of human milk as a biological system and that expand our understanding of the myriad factors influencing the composition and function of human milk using a systems biology approach.

Budget: NICHD intends to commit \$2,000,000 in FY 2022 to fund 1-8 awards. Application budgets are limited to \$499,999 in direct costs per year (exclusive of subcontracts F&A) and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. National Institute of Mental Health (NIMH) Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-228](#)

Type: R21

Application Due Date: September 7, 2021; September 7, 2022; September 7, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Consistent with the NIH global health research mission, NIMH is committed to developing clinical research expertise and sustainable research infrastructure both outside and within the United States. Although this research education opportunity is primarily for US programs, NIMH also encourages U.S.-based **applications with Low- and Middle-Income Country (LMIC) sites**. Inter-institutional collaborations could be useful when US institutions with foreign sites are involved and should build upon the pairing of mentors from different locations for an integrated approach. **SA institutions can not directly apply.**

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- **Research Experiences**
- **Mentoring Activities**

Both research experiences and mentoring activities are required. These Research Education Mentoring Programs are expected to enhance the professional development of the mentees and foster career trajectories towards independent research to reduce the incidence of HIV worldwide and to decrease the burden of living with HIV. The terms participant and mentee are used throughout this FOA to refer to individuals who are enrolled in the research education program.

Budget: Application budgets may not exceed \$200,000 in direct costs annually and are expected to reflect the actual needs of the proposed project. The total project period for an application may not exceed five years.

7. Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) – Research (Collaborative U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-TW-21-001](#)

Type: U01

Application Due Date: July 08, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications for research projects in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats. These hubs are expected to conduct the research and training needed to identify and design mitigation strategies for the adverse consequences of environmental exposures and inform relevant policy development in LMICs. The global network of hubs will serve as a platform for coordinated research and research training. GEOHealth Hubs are expected to provide leadership in environmental and occupational health research and in training a new generation of environmental and occupational health experts.

Budget: FIC and partner components intend to commit an estimated total of \$4.2 million for FY2022 for the combined linked (U01 and U2R) awards, corresponding to approximately seven linked hub awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The application budget should be developed in close coordination with the linked U2R research training application ([RFA-TW-21-002](#)) because the combined budget for both linked applications cannot exceed \$600,000 in total costs per year (including 8% F&A), and at least 50% of the combined budget must be in the LMIC's U01 application. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

8. Systems Approach to Understand Mechanisms of Heterogeneous Response to Influenza (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-21-017](#)

Type: R01

Application Due Date: September 08, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the identification of mechanisms behind heterogeneous responses in the population to influenza infection and/or vaccination through development and application of computational tools.

Budget: NIAID intends to commit \$4.0 million in FY 2022 to fund 4-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-175](#)

Type: R01

Application Due Date: October 08, 2021, October 07, 2022, October 06, 2023. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

Budget: Issuing IC and partner components intend to commit an estimated total of \$8 million to fund 6-9 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

10. Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-21-021](#)

Type: UG3/UH3

Application Due Date: July 01, 2021, October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.

Budget: NINDS intends to commit \$4,000,000 to support 3-5 awards per fiscal year. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants should rarely exceed \$1,000,000 direct costs per year for the UG3 phase and \$1,500,000 direct costs per year for the UH3 phase. The proposed project period for the UG3 phase must not exceed 4 years. The proposed project period for the UH3 phase must not exceed 4 years. The total duration of the UG3 and UH3 may not exceed 5 years.

11. Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD Small Research Grant Program

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-21-221](#)

Type: R03

Application Due Date: June 16, 2021, October 16, 2021; February 16, 2022; June 16, 2022 **AIDS dates:** September 07, 2021, January 07, 2022, May 07, 2022; September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources. The R03 program may be used for different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Budget: Application budgets are limited to \$50,000 in direct costs per year. The maximum project period is two years.

12. Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-230](#)

Type: R34

Application Due Date: July 01, 2021; March 01, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: National Institute of Mental Health (NIMH) seeks applications for pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach, to address whether the intervention engages the target mechanisms presumed to underlie the intervention effects, and to obtain preliminary data needed to inform a larger, more definitive test of the intervention.

Budget: NIMH intends to commit a total of \$1.25M in FY 2022 and FY 2023 to fund up to 5 awards depending on the submission of a sufficient number of meritorious applications. Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed three years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: [Christa](mailto:cdevries@sun.ac.za)
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | [t: +27 21 938 9838](tel:+27219389838)

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: [Lizél](mailto:lizelk@sun.ac.za)
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | [t: +27 21 808 2105](tel:+27218082105)



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

17 May 2021 (#13)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-21-180](#)

Type: R34

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. **Aids dates:** September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.

Budget: Direct costs are limited to \$450,000 over the 3-year project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted may not exceed three years.

2. Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-21-205](#)

Type: R34

Application Due Date: **Aids dates:** September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. "Intervention" here may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition or transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

Budget: Direct costs are limited to \$450,000 over a three-year period, with no more than \$225,000 in direct costs allowed in any single year. The maximum period is 3 years.

3. Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-21-219](#)

Type: R21

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. **Aids dates:** September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. While this funding opportunity also accepts clinical trials, only applications proposing “mechanistic clinical trials or studies” (studying pathophysiology or mechanism of action of an intervention, but not safety or efficacy) or basic experimental studies with humans (BESH) will be supported. For information on NIH clinical trial definitions and the types of clinical trials that are within scope of this funding opportunity announcement refer to the NIH Definition of a Clinical Trial page and the Funding Opportunity Description.

Budget: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is two years.

4. NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-21-235](#)

Type: R21

Application Due Date: June 16, 2021, October 16, 2021, February 16, 2022, June 16, 2022. **Aids dates:** September 07, 2021, January 07, 2022, May 07, 2022, September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is two years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizel*
e: lizelk@sun.ac.za | t: +27 21 808 2105



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

24 May 2021 (#14)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. National Institute of Neurological Disorders and Stroke ([NINDS](#)) Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-237](#)

Type: UG3/UH3

Application Due Date: June 25, 2021; October 13, 2021; February 09, 2022; June 09, 2022 **Aids dates:** September 07, 2021; January 07, 2022; May 07, 2022; September 07, 2022. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<https://www.ninds.nih.gov/>). For purposes of this FOA, the proposed study should be intended to prevent or treat a neurological disorder. This FOA will only support Phase 3 or Phase 4 clinical trials conducted to provide a definitive answer regarding the safety and efficacy of an intervention or to compare the effectiveness of two or more interventions. The proposed research must address a scientifically important question, provide valuable information to the existing knowledge base, and have public health relevance. The trial design should ensure that high quality, complete data regarding the primary outcome will be collected in the most efficient manner in terms of time, resources, and burden to subjects. Secondary outcomes should be included only when they are anticipated to provide important supportive or explanatory data. The necessity of each secondary endpoint must be justified in light of cost and burden. Pragmatic trials requiring minimal data collection and low cost per subject are encouraged. This FOA also may be used for the submission of an adaptive trial utilizing a seamless Phase 2/3 transition where data from subjects in Phase 2 are included in the analysis of Phase 3.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-TW-21-004](#)

Type: D43

Application Due Date: August 20, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: Although Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply, this is an opportunity to work with your collaborators in the USA. Only institutions and research sites in LMICs, as defined by the World Bank classification system (<http://data.worldbank.org/about/country-and-lending-groups>) and as restricted by [NOT-TW-12-011](#) 'Notice of Change in Country Eligibility for Fogarty International Training Grants', are eligible to participate; foreign trainees must be nationals of these eligible countries. The purpose of this program is to provide opportunities for up to six consortia to develop or expand global health research training programs that meet the following objectives: (1) provide one-year mentored research training for pre-doctoral students from the U.S. and recent post-doctoral and post-professional degree graduates (collectively referred to as trainees) from the U.S. and low- and middle- income countries (LMICs) in global health research at established biomedical and health research institutions and project sites in LMICs, particularly those supported by the NIH; (2) provide training opportunities within broad areas of research relevant to the health priorities of collaborating LMICs and aligned with the scientific priorities across the NIH Institutes, Centers, and Offices; (3) provide the solid scientific research foundation needed for trainees to rigorously develop and conduct research and effectively communicate research findings with increasing independence, with the goal of enhancing the global health research career potential of the trainees; and (4) provide more equitable access to and inclusive participation in this program to diverse populations in the U.S..

This Funding Opportunity Announcement (FOA) allows mentored training of trainees to serve as the lead investigator of an independent clinical trial or in a separate ancillary clinical trial, or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: The issuing IC and partner components intend to commit an estimated total of \$6.2 million in FY 2022 to fund up to six awards. Application budgets are limited to up to \$1 million in direct costs/year per award. The total project period for an application submitted in response to this Funding Opportunity Announcement may not exceed 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

31 May 2021 (#15)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

[NOT-RM-21-029](#) Notice Announcing Data Generation Projects for the NIH Bridge to Artificial Intelligence (Bridge2AI) Program (OT2) Other Transaction Opportunity Announcement. This Notice announces the publication of a new Research Opportunity Announcement (ROA), Data Generation Projects for the [NIH Bridge to Artificial Intelligence \(Bridge2AI\) Program](#), and the key dates for submitting Letters of Intent (LOI) and full proposals. The ROA was released on the [NIH Common Fund website](#). Non-domestic (non-U.S.) Entities (Foreign Applicants) are eligible to apply. The overall goal of the Bridge2AI Program is to generate flagship datasets and best practices for the collection and preparation of AI/ML-ready data to address biomedical and behavioral research grand challenges. The Bridge2AI program will require multiple scientific domains to come together with data science, data management and analytic experts to unlock the potential of AI/ML for the scientific community. Data Generation Project Letter of Intent (LOI) Due Date (Required): 20 July 2021. Full Proposal Deadline, due by 5 p.m. submitter's local time: 20 August 2021. The planned budget for this effort is approximately \$96 million over a 4-year period. NIH anticipates making 5-8 data generation awards.

[NOT-CA-21-081](#) Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed). CTD2 will promote efforts to radically improve our understanding of the underlying etiology of cancer initiation, progression, and metastasis and to exploit this knowledge in clinically relevant context which includes intra-tumor heterogeneity, tumor microenvironment and other factors that result in "innate" or acquired treatment resistance. Each U01 application budget will be limited to \$750,000 direct cost per year for a total of five years. Non-domestic (non-U.S.) Entity (Foreign Organization) will be eligible to apply. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

[NOT-HD-21-032](#) Notice of Special Interest (NOSI): Reduction of Sudden Unexpected Infant Death and Sudden Infant Death Syndrome. Eunice Kennedy Shriver National Institute of Child Health and Human Development ([NICHD](#)) Invite basic science, clinical researchers, behavioral scientists and implementation science experts either as individual or as multi-disciplinary teams, to submit research projects that will identify risk-reduction strategies that address infant mortality domestically, as well as efforts to understand the root causes of sudden infant death syndrome and sudden unexpected infant death. This notice applies to standard due dates starting with cycle III, 2021 (after 16 June 2021) and subsequent receipt dates through 8 May 2023. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.

- [PA-20-183](#) - Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-185](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-200](#) - NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-230](#)

Type: D43

Application Due Date: 13 August 2021; 13 July 2022; 13 July 2023 Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. Interdisciplinary research training that cuts across NCDs is encouraged. However, for more topical applications, the main focus of research training covered in the application must be relevant to the mission and/or interests of at least one of the participating NIH ICs, other than FIC, as stated by each in this FOA. Other NCD topics and types of training may be included as secondary and complementary focus areas. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Application budgets are limited to \$230,000 per year for new awards and \$250,000 per year for renewal awards (total direct costs). The maximum project period is up to 5 years.

2. Mechanistic studies on the impact of social inequality on the substance use trajectory (R21 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-005](#)

Type: R21

Application Due Date: October 14, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement [RFA-DA-22-007](#).

Budget: National Institute on Drug Abuse (NIDA) intends to commit \$2,000,000 in FY 2022 to fund 4-6 awards in response to this FOA and the companion FOAs. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

3. Assessing the Effects of Cannabinoids on HIV-Associated Persistent Inflammation (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-012](#)

Type: R01

Application Due Date: August 05, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying 1) the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation, and 2) its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.

Budget: NIDA intends to fund an estimate of 3-5 awards, corresponding to a total of \$2 million, for fiscal year 2022. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Mechanistic Studies on the Impact of Social Inequality on the Substance Use Trajectory (R01 Basic Experimental Studies with Humans Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-024](#)

Type: R01

Application Due Date: October 14, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This funding opportunity announcement (FOA) invites mechanistic studies on the impact of social inequality on the brain and on the substance use trajectory. Applications investigating relevant mechanisms at the behavioral, cognitive, neurocircuitry, cellular, genetics, and epigenetics levels are encouraged.

Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Applicants with exploratory and high-risk research projects should consider applying to the companion R01 announcement [RFA-DA-22-030](#).

Budget: NIDA intends to commit \$2 million in FY 2022 to fund 4-6 awards in response to this FOA and the companion FOAs. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-MH-21-225](#)

Type: R01

Application Due Date: August 27, 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites research grant applications that propose studies for adapting immunotherapy and gene therapy-based strategies to target viral reservoirs in the central nervous system (CNS) and examine the potential risks of applying such technologies to the brain. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 FOA, [RFA-MH-21-226](#), while applicants with preliminary data may wish to apply using the R01 mechanism.

Budget: NIMH intends to commit a total of \$2,000,000 in FY 2022 to fund 3-5 awards in response to this FOA and the companion FOA. NINDS intends to commit a total of \$1,500,000 in FY22 to fund 2-3 awards in response to this FOA and the companion FOA. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

7 Jun 2021 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

[NOT-OD-21-128](#) Updated Process for Submission of Federal Financial Reports for Closed Payment Management System Subaccounts. The purpose of this Notice is to provide instructions to NIH recipients who need to submit an SF-425 Federal Financial Report (FFR) for a closed subaccount (e.g. "C" status) in the HHS Payment Management System (PMS).

[NOT-OD-21-138](#) NIH Final Federal Financial Reports (FFRs) will be converted to Interim Annual Reports in the Payment Management System. The purpose of this Notice is to provide an update to NIH recipients who need to submit an SF-425 Federal Financial Report (FFR).

[NOT-HD-21-039](#) Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Therapies and Tools for Screenable Disorders in Newborns. The purpose of this Notice is to inform the scientific community that the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) plans to reissue three Funding Opportunity Announcements (FOAs), [PAR-18-689](#), [PAR-18-690](#), and [PAR-18-691](#), "Innovative Therapies and Tools for Screenable Disorders in Newborns. When reissued, these FOAs will continue to use the R01, R03, and R21 activity codes, respectively, and will continue to be clinical trial optional. The Specific Areas of Research Interest in these FOAs will be updated to include new and revised research priorities. This Notice informs potential applicants of the future availability of continued opportunities to submit applications beyond the 8 May 2021 expiration of the FOAs. Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AA-21-010](#)

Type: U01

Application Due Date: 16 August 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#)) seeks applications to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.

Budget: NIAAA intends to commit a combined \$4.6 million in total costs in FY2022 to fund this FOA and its companion FOAs. Up to eight U01 applications are expected to be funded from this FOA. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AA-21-014](#)

Type: UH2

Application Due Date: 16 August 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#)) seeks applications to continue the previously funded “Collaborative Initiative on Fetal Alcohol Spectrum Disorders” (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects of the CIFASD consortium.

Budget: NIAAA intends to commit a combined \$4.6 million in total costs in FY2022 to fund this FOA and its companion FOAs ([RFA-AA-21-010](#), [RFA-AA-21-011](#), [RFA-AA-21-012](#), [RFA-AA-21-013](#)). Up to three UH2 applications are expected to be funded from this FOA. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

3. Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-22-016](#)

Type: R61/R33

Application Due Date: 14 October 2021. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics.

Budget: National Institute on Drug Abuse ([NIDA](#)) intends to commit \$ 3.5M in FY 2022 to fund 2-5 awards across this and the companion FOAs. Application direct costs are limited to \$250,000 during each year of the R61 phase and \$500,000 during each year of the R33 phase. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105